Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 4/20 | 0.75 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.75 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.54 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.52 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.52 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.51 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | TDP2 | O95551 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
| ▸ | CASP9 | P55211 | 1/20 | 0.46 |
| ▸ | CASP6 | P55212 | 1/20 | 0.46 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxindole SCHEMBL28780321 | 0.94 | AHR (0.66) | AHRPDK2PDE3BPDE3ANPC1 | |
| Oxindole SCHEMBL3802438 | 0.93 | AHR (0.81) | AHRPDK2PDE3BPDE3ANPC1 | |
| Oxindole SCHEMBL14324689 | 0.89 | AHR (0.75) | AHRPDK2PDE3BPDE3ANPC1 | |
| Oxindole SCHEMBL29260649 | 0.89 | AHR (0.95) | AHRPDK2NPC1MAPK13MAPK12 | |
| Oxindole SCHEMBL29358826 | 0.87 | AHR (1.00) | AHRPDK2PDE3BPDE3ANPC1 | |
| Oxindole SCHEMBL19504 | 0.87 | AHR (1.00) | AHRPDK2PDE3BPDE3ANPC1 | |
| Oxindole SCHEMBL1144643 | 0.87 | AHR (1.00) | AHRPDK2PDE3BPDE3ANPC1 | |
| Biphenyl SCHEMBL29191442 | 0.85 | AHR (0.88) | AHRPDK2PDE3BPDE3ANPC1 | |
| Oxindole SCHEMBL5502064 | 0.85 | AHR (0.95) | AHRPDK2PDE3BPDE3ANPC1 | |
| Oxindole SCHEMBL5624006 | 0.85 | AHR (0.95) | AHRPDK2PDE3BPDE3ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111875581-A | Indolylpyridine oxide salt with novel structure and preparation method and application thereof | 河南大学 | 2020-11-03 | — | — | CN | claimed |
| CN-111875581-A | Indolylpyridine oxide salt with novel structure and preparation method and application thereof | 河南大学 | 2020-11-03 | — | — | CN | disclosed |
| US-7488743-B2 | Indolin-2-one pyridine derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2009-02-10 | — | — | US | disclosed |
| US-7488743-B2 | Indolin-2-one pyridine derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2009-02-10 | — | — | US | disclosed |
| US-7488743-B2 | Indolin-2-one pyridine derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2009-02-10 | — | — | US | disclosed |
| CN-101022813-A | Pyridine derivatives of indolin-2-ones, process for their preparation and their therapeutic use | SANOFI AVENTIS (FR) | 2007-08-22 | — | — | CN | disclosed |
| US-20070185166-A1 | Indolin-2-one Pyridine Derivatives, Preparation And Therapeutic Use Thereof | SANOFI-AVENTIS (FR) | 2007-08-09 | — | — | US | disclosed |
| US-20070185166-A1 | Indolin-2-one Pyridine Derivatives, Preparation And Therapeutic Use Thereof | SANOFI-AVENTIS (FR) | 2007-08-09 | — | — | US | disclosed |
| US-20070185166-A1 | Indolin-2-one Pyridine Derivatives, Preparation And Therapeutic Use Thereof | SANOFI-AVENTIS (FR) | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185166-A1 | Indolin-2-one Pyridine Derivatives, Preparation And Therapeutic Use Thereof | IDO1, IDO2, TPH1 | AHR 185/4885PDK2 143/4885PDE3B 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.